{
    "code": "60001176",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001176",
    "time": "2024-01-18 19:42:36",
    "許可證字號": "衛部菌疫輸字第001176號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/09\/30",
    "發證\/登錄日期": "110\/09\/30",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000117608",
    "中文品名": "祈萊亞靜脈輸注用懸浮液",
    "英文品名": "Kymriah suspension for intravenous infusion",
    "適應症": "經過基因修飾的自體免疫細胞療法，適用於治療：\r\n•患有難治型、移植後復發、第二次或二次以上復發之B細胞急性淋巴性白血病（ALL）的25歲以下兒童和年輕成人病人。\r\n•經兩線或兩線以上全身治療後之復發性或難治性瀰漫性大B細胞淋巴瘤（DLBCL）的成人病人。\r\n•經兩線或兩線以上全身治療後之復發性或難治性濾泡性淋巴瘤（FL）成人病人。",
    "劑型": "270注射劑",
    "包裝": "EVA Infusion Bag 注射軟袋裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "其他_新成分;",
    "監視期限": "115\/09\/30",
    "主成分略述": "Tisagenlecleucel (CTL019 cells)",
    "限制項目": "02輸　入 1D須執行風險管理計畫",
    "申請商名稱": "台灣諾華股份有限公司",
    "申請商地址": "臺北市中山區民生東路3段2號8樓",
    "主製造廠": [
        {
            "製造廠名稱": "NOVARTIS PHARMA STEIN AG NOVARTIS TECHNICAL OPERATIONS SCHWEIZ, STEIN CELL AND GENE THERAPY",
            "製造廠廠址": "SCHAFFHAUSERSTRASSE, 4332 STEIN, SWITZERLAD",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "原料藥、成品製造廠、包裝廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1000000500",
            "成分名稱": "Tisagenlecleucel (CTL019 cells)",
            "含量描述": "1.2 x 10^6 to 6.0 x 10^8 CAR-positive viable T cells",
            "含量": "0.0000000000",
            "單位": "Q.S."
        }
    ],
    "仿單外盒": [
        {
            "title": "8.標籤核定本_Kymriah LBL_TWL-240921_P02_clean-110-10-29.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001176&Seq=001&Type=8"
        }
    ]
}